ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in ...

The National Institutes of Health (NIH) is following in the FDA’s footsteps—away from animal testing.  | The National ...

SOUTH SAN FRANCISCO Calif. and SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ...

ORIC Pharmaceuticals, Inc. announced the presentation of preclinical data on ORIC-944, a selective allosteric inhibitor of PRC2, at the 2025 American Association for Cancer Research Annual Meeting ...

The recent news that the NIH will require universities to certify their diversity programs comply with federal civil rights law created understandable anxiety in the academic community.

In this article, we are going to take a look at where ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators ...

Alison Cernich, the agency’s acting director, directed questions to the main NIH press office when asked for confirmation. The press office did not respond to requests for comment made on ...

Kevin Hall, a top nutrition researcher at the National Institutes of Health (NIH), said he is retiring early, claiming his work was censored after Robert F. Kennedy Jr. took the helm of the ...